Matrix Metalloproteinases in Pulmonary and Central Nervous System Tuberculosis-A Review

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2019 Mar 21

PMID 30889803

Citations 21

Authors

Ursula K Rohlwink

Naomi F Walker

Alvaro A Ordonez

Yifan J Li

Elizabeth W Tucker

Paul T Elkington

Robert J Wilkinson

Katalin A Wilkinson

Affiliations

Soon will be listed here.

Abstract

Tuberculosis (TB) remains the single biggest infectious cause of death globally, claiming almost two million lives and causing disease in over 10 million individuals annually. Matrix metalloproteinases (MMPs) are a family of proteolytic enzymes with various physiological roles implicated as key factors contributing to the spread of TB. They are involved in the breakdown of lung extracellular matrix and the consequent release of bacilli into the airways. Evidence demonstrates that MMPs also play a role in central nervous system (CNS) tuberculosis, as they contribute to the breakdown of the blood brain barrier and are associated with poor outcome in adults with tuberculous meningitis (TBM). However, in pediatric TBM, data indicate that MMPs may play a role in both pathology and recovery of the developing brain. MMPs also have a significant role in HIV-TB-associated immune reconstitution inflammatory syndrome in the lungs and the brain, and their modulation offers potential novel therapeutic avenues. This is a review of recent research on MMPs in pulmonary and CNS TB in adults and children and in the context of co-infection with HIV. We summarize different methods of MMP investigation and discuss the translational implications of MMP inhibition to reduce immunopathology.

Citing Articles

Elevated Plasma Matrix Metalloproteinases Are Associated With Mycobacterium tuberculosis Bloodstream Infection and Mortality in Human Immunodeficiency Virus-Associated Tuberculosis.

Walker N, Schutz C, Ward A, Barr D, Opondo C, Shey M J Infect Dis. 2024; 231(1):109-114.

PMID: 39219411 PMC: 7616822. DOI: 10.1093/infdis/jiae296.

Pathogenesis of Post-Tuberculosis Lung Disease: Defining Knowledge Gaps and Research Priorities at the Second International Post-Tuberculosis Symposium.

Auld S, Barczak A, Bishai W, Coussens A, Dewi I, Mitini-Nkhoma S Am J Respir Crit Care Med. 2024; 210(8):979-993.

PMID: 39141569 PMC: 11531093. DOI: 10.1164/rccm.202402-0374SO.

Genome-Wide Association Study Reveals Quantitative Trait Loci and Candidate Genes Associated with High Interferon-gamma Production in Holstein Cattle Naturally Infected with .

Badia-Bringue G, Canive M, Vazquez P, Garrido J, Fernandez A, Juste R Int J Mol Sci. 2024; 25(11).

PMID: 38892353 PMC: 11172856. DOI: 10.3390/ijms25116165.

Interactions between CNS and immune cells in tuberculous meningitis.

Ma Q, Chen J, Kong X, Zeng Y, Chen Z, Liu H Front Immunol. 2024; 15:1326859.

PMID: 38361935 PMC: 10867975. DOI: 10.3389/fimmu.2024.1326859.

Recent advances in understanding the human host immune response in tuberculous meningitis.

Barnacle J, Davis A, Wilkinson R Front Immunol. 2024; 14:1326651.

PMID: 38264653 PMC: 10803428. DOI: 10.3389/fimmu.2023.1326651.

References

Vaillant C, Hutter A, Belin M, Thomasset N . Spatiotemporal expression patterns of metalloproteinases and their inhibitors in the postnatal developing rat cerebellum. J Neurosci. 1999; 19(12):4994-5004. PMC: 6782674. View

ROTHENBERG , Nelson , Hande . New Drugs on the Horizon: Matrix Metalloproteinase Inhibitors. Oncologist. 1999; 3(4):271-274. View

Matsuura E, Umehara F, Hashiguchi T, Fujimoto N, Okada Y, Osame M . Marked increase of matrix metalloproteinase 9 in cerebrospinal fluid of patients with fungal or tuberculous meningoencephalitis. J Neurol Sci. 2000; 173(1):45-52. DOI: 10.1016/s0022-510x(99)00303-2. View

Leppert D, Leib S, Grygar C, Miller K, Schaad U, Hollander G . Matrix metalloproteinase (MMP)-8 and MMP-9 in cerebrospinal fluid during bacterial meningitis: association with blood-brain barrier damage and neurological sequelae. Clin Infect Dis. 2000; 31(1):80-4. DOI: 10.1086/313922. View

Hernandez-Pando R, Orozco H, Arriaga K, Pavon L, Rook G . Treatment with BB-94, a broad spectrum inhibitor of zinc-dependent metalloproteinases, causes deviation of the cytokine profile towards type-2 in experimental pulmonary tuberculosis in Balb/c mice. Int J Exp Pathol. 2000; 81(3):199-209. PMC: 2517727. DOI: 10.1046/j.1365-2613.2000.00152.x. View

Price N, Farrar J, Tran T, Nguyen T, Tran T, Friedland J . Identification of a matrix-degrading phenotype in human tuberculosis in vitro and in vivo. J Immunol. 2001; 166(6):4223-30. DOI: 10.4049/jimmunol.166.6.4223. View

Yong V, Power C, Forsyth P, Edwards D . Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci. 2001; 2(7):502-11. PMC: 7097548. DOI: 10.1038/35081571. View

Asahi M, Wang X, Mori T, Sumii T, Jung J, Moskowitz M . Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J Neurosci. 2001; 21(19):7724-32. PMC: 6762894. View

Sternlicht M, Werb Z . How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol. 2001; 17:463-516. PMC: 2792593. DOI: 10.1146/annurev.cellbio.17.1.463. View

10.

Coussens L, Fingleton B, Matrisian L . Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science. 2002; 295(5564):2387-92. DOI: 10.1126/science.1067100. View

11.

Rosenberg G . Matrix metalloproteinases in neuroinflammation. Glia. 2002; 39(3):279-91. DOI: 10.1002/glia.10108. View

12.

Visse R, Nagase H . Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res. 2003; 92(8):827-39. DOI: 10.1161/01.RES.0000070112.80711.3D. View

13.

Thwaites G, Simmons C, Quyen N, Chau T, Mai P, Dung N . Pathophysiology and prognosis in vietnamese adults with tuberculous meningitis. J Infect Dis. 2003; 188(8):1105-15. DOI: 10.1086/378642. View

14.

Price N, Gilman R, Uddin J, Recavarren S, Friedland J . Unopposed matrix metalloproteinase-9 expression in human tuberculous granuloma and the role of TNF-alpha-dependent monocyte networks. J Immunol. 2003; 171(10):5579-86. DOI: 10.4049/jimmunol.171.10.5579. View

15.

Rosenberg G, Mun-Bryce S . Matrix metalloproteinases in neuroinflammation and cerebral ischemia. Ernst Schering Res Found Workshop. 2004; (47):1-16. DOI: 10.1007/978-3-662-05426-0_1. View

16.

van den Bos F, Terken M, Ypma L, Kimpen J, Nel E, Schaaf H . Tuberculous meningitis and miliary tuberculosis in young children. Trop Med Int Health. 2004; 9(2):309-13. DOI: 10.1046/j.1365-3156.2003.01185.x. View

17.

Lee K, Kim E, Yang W, Ryu H, Cho S, Lee B . Persistent increase of matrix metalloproteinases in cerebrospinal fluid of tuberculous meningitis. J Neurol Sci. 2004; 220(1-2):73-8. DOI: 10.1016/j.jns.2004.02.008. View

18.

Tayebjee M, Nadar S, Blann A, Beevers D, MacFadyen R, Lip G . Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Am J Hypertens. 2004; 17(9):764-9. DOI: 10.1016/j.amjhyper.2004.05.019. View

19.

Izzo A, Izzo L, Kasimos J, Majka S . A matrix metalloproteinase inhibitor promotes granuloma formation during the early phase of Mycobacterium tuberculosis pulmonary infection. Tuberculosis (Edinb). 2004; 84(6):387-96. DOI: 10.1016/j.tube.2004.07.001. View

20.

Elkington P, Nuttall R, Boyle J, OKane C, Horncastle D, Edwards D . Mycobacterium tuberculosis, but not vaccine BCG, specifically upregulates matrix metalloproteinase-1. Am J Respir Crit Care Med. 2005; 172(12):1596-604. DOI: 10.1164/rccm.200505-753OC. View